272
Participants
Start Date
June 1, 2019
Primary Completion Date
September 4, 2025
Study Completion Date
October 15, 2025
Atezolizumab
"For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle."
Enfortumab Vedotin
Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
Niraparib
Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
Magrolimab (Hu5F9-G4)
Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
Tiragolumab
Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
Sacituzumab Govitecan
Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
Tocilizumab
Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Cisplatin
Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
Gemcitabine
Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Memorial Sloan-Kettering Cancer Center, Commack
Attiko Hospital University of Athens, Athens
Hospital Universitario Reina Sofia, Córdoba
Centre Francois Baclesse, Caen
Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela
Hospital General Universitario Gregorio Mara, Madrid
MD Anderson Cancer Center, Madrid
Hospital Universitario Fundacion Jimenez Diaz., Madrid
Hospital Univ 12 de Octubre, Madrid
START Madrid. Centro Integral Oncologico Clara Campal, Madrid
Levine Cancer Institute, Charlotte
Clinica Universitaria de Navarra, Pamplona
Institut Claudius Regaud, Toulouse
Institut régional du Cancer Montpellier, Montpellier
Norton Cancer Institute, Louisville
University of Kentucky Chandler Medical Center, Lexington
University Hospitals Cleveland Medical Center, Cleveland
Cleveland Clinic, Cleveland
Hospital Clinico Universitario de Valencia, Valencia
Centre Leon Berard, Lyon
UCLA Department of Medicine, Los Angeles
UCSF Comprehensive Cancer Ctr, San Francisco
Stanford Cancer Center, Stanford
The University of Texas MD Anderson Cancer Center, Houston
Athens Medical Center, Athens
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Severance Hospital, Seoul
ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO, L'Hospitalet de Llobregat
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
Hospital Clinic i Provincial, Barcelona
Barts and The London, London
Royal Marsden NHS Foundation Trust, Sutton
Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas
UNKNOWN
Hoffmann-La Roche
INDUSTRY